Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inhaled pegylated adrenomedullin (PEG-ADM) for ARDS
2019-001078-27Phase 2Terminated
- Sponsor
- Bayer
- Start
- Apr 2020
- Modality
- Peptides, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in acute respiratory distress syndrome (ARDS) comparing Inhaled BAY 1097761 with Placebo inhalation (2 arms). Primary endpoint: Ventilator-free survival at day 28 (Part B). Started Apr 2020; status: terminated.
02
Drugs
adrenomedullin pegol
03
Conditions
acute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on 2019-001078-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001078-27.